Evaluation of creatinine-based formulas in dosing adjustment of cancer drugs other than carboplatin

Abstract

Background. Glomerular filtration rate (GFR) is often used to determine initial dosing of renally excreted cancer drugs. GFR can be calculated using the Cockcroft-Gault (CG) or the modified diet in renal diseases (MDRD) study formulas, both of which are based on serum creatinine levels. The MDRD formula is more accurate in noncancer patients, does not require patient weight, and is reported automatically by all laboratories in British Columbia, Canada. We previously showed that the CG and MDRD formulas have similar accuracy for carboplatin dosing in patients with gynecological malignancies. We now examine dosing of all renally excreted cancer drugs in the general cancer population. Since this setting does not include routine measurement of GFR, we report the concordance of estimates of GFR derived from the CG and MDRD formulas.

Methods. Patient data were collected retrospectively at the BC Cancer Agency. The primary outcome was the proportion of patients who would have received a different initial dose due to difference in the GFR. Each patient’s dose was determined from dose adjustment tables stated in specific treatment protocols. The secondary outcome was concordance of the GFR derived from CG and MDRD, using the method of Bland and Altman. A difference of >30% was assumed to be clinically significant because this difference would usually lead to dose adjustment based on reclassification of renal function.

Results. A total of 313 patients were evaluated, with 40% male. The median age was 56 years, weight 67.5 kg, height 166 cm, and serum creatinine 74 µmol/L (0.84 mg/dL). The median GFR derived from the CG and MDRD formulas were 86.8 mL/min (mean 91 mL/min, SD ± 30 mL/min) and 87.6 mL/min (mean 88 mL/min, SD ± 26 mL/min), respectively. A total of 8.6% (27/313) of patients would have received a different dose due to difference in the GFR; of these, 67% (18/27) would have received a higher dose. A difference of >30% in GFR was found in 17.9% (56/313) of patients.

Conclusions. There is good concordance of the GFR derived from the CG and MDRD formulas for most cancer patients, with less than 10% of patients expected to receive a different initial dose of chemotherapy. The MDRD formula may be a reasonable alternative to the CG formula for dosing of cancer drugs which are renally excreted or nephrotoxic. J Oncol Pharm Practice (2010) 16: 113—119.

Keywords

renal function golmerular filtration rate antineoplasitc agents

Get full access to this article

View all access options for this article.

References

Cockcroft D. , Gault M. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.

McDermott DF , Galindo A. , Sherman RL , Jaffe EA , Coleman M. , Pasmantier MW Inadequacy of predicted creatinine clearance as guide to chemotherapy. Cancer Treat Rep 1987; 71(11): 1067-93.

Chambers JT , Chambers SK , Schwartz PE Correlation between measured creatinine clearance and calculated creatinine clearance in ovarian cancer patients. Gynecol Oncol 1990; 36(1): 66-68.

Montgomery MJ , Beringer PM , Louie SG , Gill MA Estimation of creatinine clearance in patients with metastatic ovarian cancer. Ther Drug Monit 2000; 22(6): 695-700.

Millward MJ , Webster LK , Toner GC , Bishop JF , Rischin D. , Stokes KH Carboplatin dosing based on measurement of renal function-experience at the Peter MacCallum Cancer Institute. Aust N Z J Med 1996; 26(3): 372-79.

Calvert AH , Boddy A. , Bailey NP , Siddiqui N. , Humphreys A. , Hughes A. Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions [erratum appears in Semin Oncol 1996 Dec; 23(6): 781]. Semin Oncol 1995; 22(5 Suppl 12): 91-98; discussion 9-100.

Calvert AH , Ghokul S. , Al-Azraqi A. , Wright J. , Lind M. , Bailey N. et al. Carboplatin and paclitaxel, alone and in combination: dose escalation, measurement of renal function, and role of the p53 tumor suppressor gene. Semin Oncol 1999; 26(1 Suppl 2): 90-94.

Chatelut E. , Chevreau C. , Brunner V. , Martinez M. , Houin G. , Bugat R. A pharmacologically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancer. Cancer Chemother Pharmacol 1995; 35(5): 391-96.

Chatelut E. , Canal P. , Brunner V. , Chevreau C. , Pujol A. , Boneu A. et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. [comment]. J Natl Cancer Inst 1995; 87(8): 573-80.

10.

van Warmerdam LJ , Rodenhuis S. , ten Bokkel Huinink WW , Maes RA , Beijnen JH Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin. Cancer Chemother Pharmacol 1996; 37(3): 266-70.

11.

Ando Y. , Minami H. , Saka H. , Chevreau C. , Pujol A. , Boneu A. et al. Adjustment of creatinine clearance improves accuracy of Calvert’s formula for carboplatin dosing. Br J Cancer 1997; 76(8): 1067-71.

12.

Donahue A. , McCune JS , Faucette S. , Gillenwater HH , Kowalski RJ , Socinski MA Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing. Cancer Chemother Pharmacol 2001; 47(5): 373-79.

13.

Wright JG , Boddy AV , Highley M. , Fenwick J. , McGill A. , Calvert AH Estimation of glomerular filtration rate in cancer patients. Br J Cancer 2001; 84(4): 452-59.

14.

Tsubaki T. , Goodin S. , Leader WG , Chandler MH Estimation of creatinine clearance in patients with gynecologic cancer . Clin Pharm 1993; 12(9): 685-90.

15.

Calvert AH A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel . Semin Oncol 1997 ; 24(1 Suppl 2): S2-85-S2-90.

16.

Fujiwara Y. , Takahashi T. , Yamakido M. , Ohune T. , Tsuya T. , Egorin MJ Re: prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1997 ; 89(3): 260-2; [comment].

17.

Minami H. , Ando Y. , Saka H. , Shimokata K. Re: prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1997; 89(13): 968-70; [comment].

18.

Okamoto H. , Nagatomo A. , Kunitoh H. , Kunikane H. , Watanabe K. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae. Cancer Chemother Pharmacol 1998; 42(4): 307-12.

19.

Thompson CA Better renal-function estimates not expected to alter drug dosing right away. Am J Health Syst Pharm 2005; 62(23): 2442-44.

20.

McNeely MDD. The estimated glomerular filtration rate: linchpin of the chronic kidney disease guidelines. B C Med J 2005; 47(6): 287-91.

21.

Levey AS , Coresh J. , Balk E. , Kausz AT , Levin A. , Steffes MW et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139(2): 137-47; [comment][erratum appears in Ann Intern Med . 2003 Oct 7; 139(7): 605].

22.

Levey AS , Greene T. , Kusek JW , Beck GJ , Group MS A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract]. J Am Soc Nephrol 2000 ; 11: A0828.

23.

Lamb EJ , Tomson CR , Roderick PJ Estimating kidney function in adults using formulae. Ann Clin Biochem 2005; 42(Pt 5): 321-45.

24.

Mathew TH Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: a position statement. Med J Aust 2005 ; 183(3): 138-41.

25.

Levey AS , Bosch JP , Lewis JB , Greene T. , Rogers N. , Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group . Ann Intern Med 1999 ; 130(6): 461-70; [comment].

26.

Myers GL , Miller WG , Coresh J. , Fleming J. , Greenberg N. , Greene T. et al. Recommendations for improving serum creatinine measurement: a report from the laboratory working group of the national kidney disease education program. Clin Chem 2006; 52(1): 5-18.

27.

Anonymous. Appendix I: European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant 2000; 15(Suppl 4): 57-63.

28.

Wolowich WR , Raymo L. , Rodriguez JC Problems with the use of the modified diet in renal disease formula to estimate renal function. Pharmacotherapy 2005; 25(9): 1283-84; discussion 4-5.

29.

Bailie GR , Uhlig K. , Levey AS Clinical practice guidelines in nephrology: evaluation, classification, and stratification of chronic kidney disease. Pharmacotherapy 2005; 25(4): 491-502.

30.

Dersch D. , McCormack J.

Estimating renal function for drug dosing: rewriting the gospel?

Can J Hosp Pharm 2008; 61(2): 138-43.

31.

de Lemos ML , Hsieh T. , Hamata L. , Levin A. , Swenerton K. , Djurdjev O. et al. Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies . Gynecol Oncol 2006; 103(3): 1063-69.

32.

Poole SG , Dooley MJ , Rischin D. Calculating carboplatin doses using the 4-variable modification of diet in renal disease (4-v MDRD) estimate of glomerular filtration rate (GFR) in the Calvert formula. J Clin Oncol (Meeting Abstracts) 2007; 25(18_suppl): 2521.

33.

Bland JM , Altman DG Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1(8476): 307-10.

34.

Bland JM , Altman DG Applying the right statistics: analyses of measurement studies. Ultrasound Obstet Gynecol 2003; 22(1): 85-93.

35.

BC Stats. 2001 Census Profile - British Columbia. Victoria, BC : Data Services, BC Stats; 27 January, 2004.

36.

de Lemos ML , Hamata L. , Conklin J. , Swenerton K. Potential underdosing of carboplatin in gynecological malignancies. Gynecol Oncol 2006; 102(3): 599.

37.

Wargo KA , Eiland III EH , Hamm W. , English TM , Phillippe HM et al. Comparison of the modification of diet in renal disease and Cockcroft-Gault equations for antimicrobial dosage adjustments. Ann Pharmacother 2006; 40(7): 1248-53.

38.

Golik MV , Lawrence KR Comparison of dosing recommendations for antimicrobial drugs based on two methods for assessing kidney function: cockcroft-gault and modification of diet in renal disease. Pharmacotherapy 2008 ; 28(9): 1125-32.

39.

Moranville MP , Jennings HR Implications of using modification of diet in renal disease versus Cockcroft-Gault equations for renal dosing adjustments . Am J Health Syst Pharm 2009 ; 66(2): 154-61.

40.

Holweger K. , Lipp HP , Dietz K. , Hartmann JT , Bokemeyer C. Novel algorithm for more accurate calculation of renal function in adults with cancer. Ann Pharmacother 2008; 42(12): 1749-57.

41.

Kleber M. , Cybulla M. , Bauchmuller K. , Ihorst G. , Koch B. , Engelhardt M. Monitoring of renal function in cancer patients: an ongoing challenge for clinical practice. Ann Oncol 2007; 18(5): 950-58.

42.

Launay-Vacher V. , Oudard S. , Janus N. , Gligorov J. , Pourrat X. , Rixe O. et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 2007; 110(6): 1376-84.

43.

Bauer L. Creatinine clearance versus glomerular filtration rate for the use of renal drug dosing in patients with kidney dysfunction. Pharmacotherapy 2005; 25(9): 1286-87.

44.

Spruill WJ , Wade WE , Cobb 3rd HH. Estimating glomerular filtration rate with a modification of renal disease equation: Implications for pharmacy. Am J Health-Syst Pharm 2007; 64(6): 652-60.

45.

McEvoy GK Dose adjustment in renal impairment: Response from AHFS Drug Information. BMJ 2005; 331(7511): 293.

46.

Aronoff GR Dose adjustment in renal impairment: response from drug prescribing in renal failure. BMJ 2005; 331(7511): 293-94.

47.

Vidal L. , Shavit M. , Fraser A. , Paul M. , Leibovici L. Systematic comparison of four sources of drug information regarding adjustment of dose for renal function. BMJ 2005; 331(7511): 263.

48.

Gelman RS , Tormey DC , Betensky R. , Mansour EG , Falkson HC , Falkson G. et al. Actual versus ideal weight in the calculation of surface area: effects on dose of 11 chemotherapy agents. Cancer Treat Rep 1987; 71(10): 907-11.

49.

Turner ST , Reilly SL Fallacy of indexing renal and systemic hemodynamic measurements for body surface area. Am J Physiol 1995; 268(4 Pt 2): R978-88.

50.

Peters AM , Henderson BL , Lui D. Indexed glomerular filtration rate as a function of age and body size . Clin Sci 2000; 98(4): 439-44.

51.

Dooley MJ , Poole SG Poor correlation between body surface area and glomerular filtration rate . Cancer Chemother Pharmacol 2000; 46(6): 523-26.

52.

Aronoff GR , Berns JS , Brier ME et al. Drug prescribing in renal failure: dosing guidelines for adults . 4th edn, Philadelphia (PA) ; American College of Physicians, 1999.

53.

International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 325(4): 351-60.